Patents by Inventor John Doedens

John Doedens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Viral vectors useful in induction of humoral or cellular immunity
    Patent number: 7247619
    Abstract: The invention features recombinant viral vectors that take advantage of the activity of picornaviral protein 3A in modulating cytokine secretion and antigen presentation on MHC Class I (MHC I), which in turn provides for modulation of a Th1-mediated immune response to the transfected host cell. Specifically, a recombinant viral vector comprising a sequence encoding picornaviral protein 3A provides for decreased antigen presentation on MHC I and a decreased incidence of Th1-mediated immune response, while a recombinant picornaviral vector that is deficient in protein 3A production provides for increased cytokine secretion, increased antigen presentation on MHC I and increased Th1-mediated immune response towards the transfected host cell. The invention also features methods of inducing humoral or cellular immunity using the vectors.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: July 24, 2007
    Inventors: Karla Kirkegaard, Dana A. Dodd, Stephen B. Deitz, John Doedens
  • Viral vectors useful in induction of humoral or cellular immunity
    Publication number: 20040052765
    Abstract: The invention features recombinant viral vectors that take advantage of the activity of picornaviral protein 3A in modulating cytokine secretion and antigen presentation on MHC Class (MHC I), which in turn provides for modulation of a Th1-mediated immune response to the transfected host cell. Specifically, a recombinant viral vector comprising a sequence encoding picornaviral protein 3A provides for decreased antigen presentation on MHC 1 and a decreased incidence of Th1-mediated immune response, while a recombinant picornaviral vector that is deficient in protein 3A production provides for increased cytokine secretion, increased antigen presentation on MHC and increased Th1-mediated immune response towards the transfected host cell. The invention also features methods of inducing humoral or cellular immunity using the vectors.
    Type: Application
    Filed: September 2, 2003
    Publication date: March 18, 2004
    Inventors: Karla Kirkegaard, Dana A. Dodd, Stephen B. Deitz, John Doedens